Impax cuts nearly 50 employees to save money

Impax Laboratories ($IPXL), which has struggled for several years to get its Parkinson's drug Rytary to market, is moving away from early-stage research and has cut its R&D staff by 42 jobs, a 25% reduction to save money. The cut of a total of 49 positions at the company is expected to save $8 million a year. From here on out, Impax's branded R&D efforts will focus on products in Phase II and above, the company said in a statement today. Ongoing FDA concerns about Impax' manufacturing has delayed approval of Rytary for some time. Story | More

Suggested Articles

After early threats, the FDA finished reviewing the company's response to a citation for data manipulation and decided not to take any further action.

China is quickly getting back up to speed with API production but reports freight bottlenecks are slowing deliveries.

Mylan and Pfizer have already postponed the close of their generic merger amid COVID-19 concerns. Now the pair is hoping to speed up EU review.